Abstract

Soluble Fibrin Monomer Complex and Cardiopulmonary Bypass

^* University of Rochester Medical Center, Rochester, New York
^† Geisinger Medical Center, Danville, Pennsylvania

Address correspondence to: Cody Trowbridge, MPS, CCP, Geisinger Medical Center, 100 N. Academy Avenue C. 20–25, Danville, PA 178222025. E-mail: cctrowbridge@geisinger.edu

Received: 31 March 2008
Accepted: 17 May 2009

Abstract

Soluble fibrin monomer complexes (SFMCs) are precursors of fibrin polymer formation. Laboratory tests can be used to detect SFMCs in plasma. The purpose of this study was to determine whether a positive SFMC test is associated with pre-operative, intra-operative, and post-operative variables for patients that have undergone cardiopulmonary bypass (CPB). Pre-operative, operative, post-operative, and laboratory data from 120 consecutive adults patients (July 3, 2006 to June 29, 2007) that had undergone cardiac surgery with the use of CPB were obtained from a prospective quality control database. Two groups were created. Group 1 was all negative (NEG). This group had no SFMC test with a positive result (n = 60) and no positive SFMCs (POS, n = 60). Group 2 was any positive (POS). This group had at least one positive SFMC test (n = 60). The POS group had more patients with endocarditis (11.7% vs. 3.3%, p < .001), chronic obstructive pulmonary disease (COPD) (18% vs. 8.3%, p = .005), longer CPB time (172 ± 64 vs. 151 ± 53 minutes, p = .047), and fewer minimally invasive procedures (31.7% vs. 51.7%, p = .002). The POS group required intraoperative (70.0% vs. 53.3%, p = .010) and post-operative (75.5% vs. 45.0%, p < .001) transfusions more frequently than the NEG group, despite similar amounts of blood loss. SFMC tests in CPB may be associated with patient pre-operative status and an increase in transfusion requirements.